Login to Your Account



AML Smacdown

Combination approach boosts new cancer therapy

By John Fox
Staff Writer

Wednesday, July 12, 2017

An international research collaboration has found a means to improve the effect of mimetics of the second mitochondrial-derived activator of caspase (Smac), a novel class of targeted cancer drugs that act by inducing apoptotic cancer cell death and inhibiting pro-survival signaling.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription